Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

In vivo modeling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastoma

Lookup NU author(s): Dr Jemma CastleORCiD, Dr Edward FielderORCiD, Mankaran Singh, Professor Roderick Skinner, Professor Thomas von Zglinicki, Professor Steven CliffordORCiD, Dr Satomi MiwaORCiD, Dr Debbie HicksORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2024 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. Background: Medulloblastoma (MB) is the most common malignant pediatric brain tumor, with 5-year survival rates > 70%. Cranial radiotherapy (CRT) to the whole brain, with posterior fossa boost (PFB), underpins treatment for non-infants; however, radiotherapeutic insult to the normal brain has deleterious consequences to neurocognitive and physical functioning, and causes accelerated aging/frailty. Approaches to ameliorate radiotherapy-induced late-effects are lacking and a paucity of appropriate model systems hinders their development. Methods: We have developed a clinically relevant in vivo model system that recapitulates the radiotherapy dose, targeting, and developmental stage of childhood medulloblastoma. Consistent with human regimens, age-equivalent (postnatal days 35-37) male C57Bl/6J mice received computerized tomography image-guided CRT (human-equivalent 37.5 Gy EQD2, n = 12) ± PFB (human-equivalent 48.7 Gy EQD2, n = 12), via the small animal radiation research platform and were longitudinally assessed for > 12 months. Results: CRT was well tolerated, independent of PFB receipt. Compared to a sham-irradiated group (n = 12), irradiated mice were significantly frailer following irradiation (frailty index; P = .0002) and had reduced physical functioning; time to fall from a rotating rod (rotarod; P = .026) and grip strength (P = .006) were significantly lower. Neurocognitive deficits were consistent with childhood MB survivors; irradiated mice displayed significantly worse working memory (Y-maze; P = .009) and exhibited spatial memory deficits (Barnes maze; P = .029). Receipt of PFB did not induce a more severe late-effect profile. Conclusions: Our in vivo model mirrored childhood MB radiotherapy and recapitulated features observed in the late-effect profile of MB survivors. Our clinically relevant model will facilitate both the elucidation of novel/target mechanisms underpinning MB late effects and the development of novel interventions for their amelioration.


Publication metadata

Author(s): Castle J, Shaw G, Weller D, Fielder E, Egnuni T, Singh M, Skinner R, Von Zglinicki T, Clifford SC, Short SC, Miwa S, Hicks D

Publication type: Article

Publication status: Published

Journal: Neuro-Oncology Advances

Year: 2024

Volume: 6

Issue: 1

Online publication date: 06/06/2024

Acceptance date: 02/04/2018

Date deposited: 17/07/2024

ISSN (electronic): 2632-2498

Publisher: Oxford University Press

URL: https://doi.org/10.1093/noajnl/vdae091

DOI: 10.1093/noajnl/vdae091

Data Access Statement: The data that support the study’s findings are available from the corresponding author (DH) upon reasonable request.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
C12161/A24009Cancer Research UK
ERC WIDESPREAD TEAMING grant (DLV-857524)
UK SPINE Proof of Concept fund, H2020 WIDESPREAD (Project: 857524, MIA Portugal)
University of Leeds Alumni Offce “Brain cancer Research at Leeds

Share